<DOC>
	<DOCNO>NCT02616250</DOCNO>
	<brief_summary>The main objective study evaluate efficacy Ivermectin 1 % cream ( IVM ) associate Brimonidine 0.33 % gel ( Br ) compare association respective vehicle treatment moderate severe rosacea .</brief_summary>
	<brief_title>MirvasO Soolantra Association In Treatment Moderate Severe rosaCea .</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Ivermectin</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>Main 1 . Male female subject age 18 year old ; 2 . Subjects minimum 15 70 inflammatory lesion ( papule pustule ) rosacea face ; 3 . Subjects moderate severe diffuse persistent facial erythema rosacea ( score 3 4 accord Clinician 's Erythema Assessment [ CEA ] ) ; 4 . Subjects moderate severe papulopustular rosacea ( score 3 4 accord Investigator 's Global Assessment [ IGA ] ) ; 5 . Female subject childbearing potential negative urine pregnancy test ( UPT ) ; 6 . Female subject childbearing potential must practice highly effective method contraception study ; 7 . Females subject nonchildbearing potential ; Main 1 . Subjects particular form rosacea concomitant facial dermatosis may confound rosacea ; 2 . Subjects 2 nodule rosacea face ; 3 . Subjects uncontrolled chronic serious disease medical condition may either interfere interpretation clinical trial result , optimal participation study would present significant risk subject ; 4 . Subjects know suspected allergy sensitivity component investigational noninvestigational product , include active ingredient brimonidine salt brimonidine like brimonidine tartrate ivermectin ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>